vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.
NATIONAL BANKSHARES INC is the larger business by last-quarter revenue ($15.3M vs $10.7M, roughly 1.4× Arbutus Biopharma Corp). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs 23.5%, a 15.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 24.7%). Over the past eight quarters, NATIONAL BANKSHARES INC's revenue compounded faster (20.9% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
ABUS vs NKSH — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $15.3M |
| Net Profit | $2.5M | $5.9M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 47.4% |
| Net Margin | 23.5% | 38.5% |
| Revenue YoY | 522.2% | 24.7% |
| Net Profit YoY | 112.7% | 91.0% |
| EPS (diluted) | $0.01 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | $10.7M | $13.3M | ||
| Q1 25 | — | $12.8M | ||
| Q4 24 | — | $12.2M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | — | $10.9M | ||
| Q1 24 | — | $10.4M |
| Q4 25 | — | $5.9M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | $2.5M | $2.3M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | — | $2.7M | ||
| Q2 24 | — | $-307.0K | ||
| Q1 24 | — | $2.2M |
| Q4 25 | — | 47.4% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | 13.9% | 20.0% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 30.1% | ||
| Q3 24 | — | 27.5% | ||
| Q2 24 | — | -4.4% | ||
| Q1 24 | — | 25.8% |
| Q4 25 | — | 38.5% | ||
| Q3 25 | — | 31.1% | ||
| Q2 25 | 23.5% | 17.2% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | — | 22.8% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | $0.93 | ||
| Q3 25 | — | $0.69 | ||
| Q2 25 | $0.01 | $0.36 | ||
| Q1 25 | — | $0.51 | ||
| Q4 24 | — | $0.50 | ||
| Q3 24 | — | $0.42 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $59.3M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $184.9M |
| Total Assets | $103.3M | $1.8B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $59.3M | ||
| Q3 25 | — | $42.3M | ||
| Q2 25 | $37.4M | $92.8M | ||
| Q1 25 | — | $122.5M | ||
| Q4 24 | — | $108.1M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $98.9M | ||
| Q1 24 | — | $121.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $184.9M | ||
| Q3 25 | — | $179.2M | ||
| Q2 25 | $83.0M | $168.7M | ||
| Q1 25 | — | $167.3M | ||
| Q4 24 | — | $156.4M | ||
| Q3 24 | — | $167.8M | ||
| Q2 24 | — | $149.0M | ||
| Q1 24 | — | $139.4M |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | $103.3M | $1.8B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $17.9M |
| Free Cash FlowOCF − Capex | — | $15.2M |
| FCF MarginFCF / Revenue | — | 99.2% |
| Capex IntensityCapex / Revenue | 0.0% | 17.9% |
| Cash ConversionOCF / Net Profit | -6.24× | 3.04× |
| TTM Free Cash FlowTrailing 4 quarters | — | $23.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.9M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $-15.7M | $2.1M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $3.8M |
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $-4.0M | ||
| Q1 24 | — | $3.5M |
| Q4 25 | — | 99.2% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 11.5% | ||
| Q1 25 | — | 12.5% | ||
| Q4 24 | — | 50.5% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | -36.3% | ||
| Q1 24 | — | 33.8% |
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | 0.0% | 4.1% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 9.3% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | 3.04× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | -6.24× | 0.90× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 3.07× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
